Results 41 to 50 of about 82,941 (302)

Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. [PDF]

, 2018
Triple Negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2.
Austin, David, Elshimali, Yahya, Hamilton, Nalo, Pietras, Richard, Vadgama, Jaydutt, Wu, Yanyuan   +5 more
core   +1 more source

Family history of breast and ovarian cancer and triple negative subtype in hispanic/latina women. [PDF]

, 2014
Familial breast and ovarian cancer prevalence was assessed among 1150 women of Mexican descent enrolled in a case-only, binational breast cancer study. Logistic regression was conducted to compare odds of triple negative breast cancer (TNBC) to non-TNBC ...
Anderson, Kristin, Bondy, Melissa, Brewster, Abenaa, Daneri-Navarro, Adrian, Gutierrez-Millan, Luis Enrique, Komenaka, Ian K, Madlensky, Lisa, Martin, Lorena, Martínez, María Elena, Meza-Montenegro, Maria Mercedes, Natarajan, Loki, Thompson, Patricia A, Tobias, Malaika, Wertheim, Betsy C   +13 more
core   +2 more sources

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. [PDF]

, 2020
PurposeThis study aimed to determine the safety, tolerability, and recommended phase II doses of trametinib plus uprosertib (GSK2141795) in patients with solid tumors likely to be sensitive to MEK and/or AKT inhibition.MethodsThis was a phase I, open ...
Becerra, Carlos, D'Amelio, Anthony M, Ellis, Catherine, Gauvin, Jennifer, Gonzalez, Rene, Heist, Rebecca S, Ibrahim, Nageatte, Kalyana-Sundaram, Shanker, Kleha, Joseph F, Kurzrock, Razelle, Leonowens, Cathrine, Means-Powell, Julie, Tan, Antoinette R, Tolcher, Anthony W, Valero, Vincente, Wang, Chenxi, Werner, Theresa L, Yan, Li   +17 more
core  

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Cytotoxicity of the urokinase-plasminogen activator inhibitor carbamimidothioic acid (4-boronophenyl) methyl ester hydrobromide (BC-11) on triple-negative MDA-MB231 breast cancer cells [PDF]

, 2015
: BC-11 is an easily synthesized simple thiouronium-substituted phenylboronic acid, which has been shown to be cytotoxic on triple negative MDA-MB231 breast cancer cells by inducing a perturbation of cell cycle when administered at a concentration equal ...
Baltus, Christine B, Chuckowree, Irina S, Librizzi, Mariangela, Longo, Alessandra, Luparello, Claudio, Spencer, John   +5 more
core   +2 more sources

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Mutant p53–Nrf2 axis regulates the proteasome machinery in cancer

Molecular & Cellular Oncology, 2017
The proteasome machinery is a common target of gain-of-function p53 missense mutants. Upregulation of the proteasome fosters chemoresistance to proteasome inhibitors.
Kamil Lisek, Dawid Walerych, Giannino Del Sal   +2 more
doaj   +1 more source

The discovery of a novel series of potential ERRα inverse agonists based on p-nitrobenzenesulfonamide template for triple-negative breast cancer in vivo

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
Oestrogen related receptor α participated in the regulation of oxidative metabolism and mitochondrial biogenesis, and was overexpressed in many cancers including triple-negative breast cancer.
Zhipei Gao, Tianxiao Wang, Rui Li, Yongli Du, Han Lv, Liudi Zhang, Haifei Chen, Xiaojin Shi, Qunyi Li, Jingkang Shen   +9 more
doaj   +1 more source

Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women. [PDF]

, 2017
Background: This study investigated the association of vitamin D3 levels with breast cancer risk and progression in African-Americans and Hispanics. Methods: A total of 237 African-American (Cases = 119, Control = 118) and 423 Hispanic women (Cases = 124,
Chlebowski, Rowan, Clayton, Sheilah, Sarkissyan, Marianna, Vadgama, Jaydutt V, Wu, Yanyuan   +4 more
core   +2 more sources